VANCOUVER, British Columbia — Statins show promise as a low-risk disease-modifying agent for treating thyroid eye disease, for which smoking is seen as the only modifiable risk factor. A hyperosmotic shift of fluid into orbital tissue is associated with thyroid eye disease, and the resultant inflammatory state can last for 1 to 2 years, Andrew L. Reynolds, MD, said at the American Association for Pediatric Ophthalmology and Strabismus meeting
Angiogenesis factor found to promote three age-related diseases of the eye
A Massachusetts General Hospital (MGH) investigator has found that increased expression of the angiogenic factor VEGF-A promotes three common aging-related eye conditions – both versions of…
Efficacy and Safety of Oral Valproic Acid for Retinitis Pigmentosa
Status: Completed,
Condition Summary: Retinitis Pigmentosa; Retinal Diseases; Eye Diseases; Eye Disease, Hereditary; Retinal Degeneration
Natural History of Eye Diseases Related to ABCA4 Mutations
Status: Recruiting,
Condition Summary: Retinal Degeneration; ABCA4-Related Retinopathies
Study quantifies significant time spent documenting in EHRs
VANCOUVER, British Columbia — Like in other ophthalmic specialties, a significant amount of the pediatric ophthalmologist’s time is spent documenting in electronic health records, perhaps detrimentally so, according to a study presented here.“There’s been a lot of anecdotal and some published evidence showing that there may be a negative impact of EHRs on efficiency by ophthalmologists,” Michael F. Chiang, MD, said at the American Association for Pediatric Ophthalmology and Strabismus meeting.
Research suggests new pathway for preventing optic nerve damage in KPro recipients
Researchers from Massachusetts Eye and Ear/Harvard Medical School have identified inflammatory factors that cause optic neuropathy in the back of the eye following implantation of a keratoprosthesis (KPro) — similar to what glaucoma patients experience, without the rise of pressure in the eye — and have shown that blocking one of those factors, tumor necrosis factor alpha (TNFa), successfully halts the development of optic nerve damage in a mouse model.